kinesin family member 18AGenealiases: MS-KIF18A · PPP1R99
Q-omics provides the consensus-scored KIF18A profile across patient tissues and cancer cell-line models. KIF18A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KIF18A is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, KIF18A RNA expression shows 24,910 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where KIF18A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF18A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF18A survival associations across molecular data types. KIF18A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF18A RNA expression–survival associations across cancer types. High KIF18A expression shows unfavorable associations in ACC, KIRP, MESO, KIRC, KICH and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KIF18A RNA expression.
This table summarizes KIF18A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KIF18A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF18A shows higher tumor expression in HNSC, KIRC, BLCA, COAD, KIRP and STAD. The HNSC box plot shows higher KIF18A RNA expression in tumor versus normal tissue (log2 FC = +1.661, t-test p < 0.001).
This table shows molecular features associated with KIF18A in patient tissues and cancer cell lines. In patient samples, KIF18A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF18A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
